Hypertension, Pregnancy-Induced Clinical Trial
Official title:
A Clinical Study of Fundus Findings in Toxaemia of Pregnancy (Pregnancy Induced Hypertension)
Toxemia of pregnancy is a recognized entity for over 2000 years with its known complications
and fatality. Nowadays, a most accepted terminology for the following defined syndrome is
"hypertensive disorders in pregnancy" given by American College of Obstetrics and
Gynecology. It is an important cause of maternal and fetal morbidity and mortality.
Pregnancy induced hypertension (PIH) was classified as gestational hypertension,
preeclampsia, severe preeclampsia and eclampsia. PIH is a hypertensive disorder in pregnancy
that occurs after 20 weeks of pregnancy in the absence of other causes of elevated blood
pressure (BP) (BP >140/90 mmHg measured two times with at least of 4 hour interval) in
combination with generalized edema and/or proteinuria (>300 mg per 24 hrs). When there is
significant proteinuria it is termed as preeclampsia; seizure or coma as a consequence of
PIH is termed as eclampsia. Preeclampsia was classified into mild and severe preeclampsia.
Mild eclampsia—BP >140/90 mmHg, proteinuria+, and/or mild edema of legs, Severe
preeclampsia—BP >160/110 mmHg,proteinuria++ or ++++, headache, cerebral or visual
disturbances, epigastric pain, impaired liver function tests and increase in serum
creatinine.
Proteinuria was tested using dipstick method as +=0.3 gm/L, ++=1 gm/L, and +++=3 gm/L.
The pathological changes of this disease appear to be related to vascular endothelial
dysfunction and its consequences (generalized vasospasm and capillary leak). Ocular
involvement is common in PIH.Common symptoms are blurring of vision, photopsia, scotomas and
diplopia. Visual symptoms may be the precursor of seizures.Progression of retinal changes
correlates with progression of PIH and also with the fetal mortality due to similar vascular
ischemic changes in placenta.Vasospastic manifestations are reversible and the retinal
vessels rapidly return to normal after delivery. Ophthalmoscope should be rated next to the
sphygmomanometer as an instrument of diagnostic importance in cases of PIH. Ophthalmoscopy
does not only helps in diagnosing the disease but repeated observations assist in assessing
the severity, progress of disease, response to treatment if any and ultimate outcome or
prognosis.
An observational study in which the patients for the study are selected from antenatal
clinic, antenatal ward and "preeclampsia and eclampsia room" in Department of Obstetrics and
Gynecology and general Ophthalmic Out Patient Department(OPD) in case of ambulatory patients
during the period of November 2003 to June 2006 randomly.In every case, detail obstetric
history including a detail antenatal history was taken. General examination and relevant
pathological investigations like routine blood count, HIV, HBsAg, renal function tests,
TORCH complex etc., were carried out. In every case, pupil was dilated with homatropine (2%)
eye drops. Then detailed ophthalmic examination was carried out with special emphasis on
direct ophthalmoscopy apart from visual acuity of both eyes and anterior segment
examination. Fundus findings were noted in detail, changes in the color of the disc, disc
margin, physiological cup, changes in retinal blood vessels especially caliber of vessels,
arterio‑venous (AV) ratio,changes in vessel wall, blood column, appearance of vascular light
reflex, changes at AV crossings, changes in macular area and changes in background, overall
appearance, presence of hemorrhages, exudates or any pathology were recorded.
Fundus changes were graded as per modified Keith, Wagner and Barker
classification.Assessment of prognosis as regards to vision and life (mortality) was made.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03613714 -
Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy
|
N/A | |
Completed |
NCT02338687 -
Low Dose Calcium to Prevent Preeclampsia
|
Phase 4 | |
Completed |
NCT04752475 -
Lasix for the Prevention of De Novo Postpartum Hypertension
|
Phase 3 | |
Completed |
NCT03334149 -
Blood Pressure Monitoring in High Risk Pregnancy to Improve the Detection and Monitoring of Hypertension
|
N/A | |
Recruiting |
NCT03298802 -
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide
|
Phase 3 | |
Recruiting |
NCT05473767 -
Expanding the Family Check-Up in Early Childhood to Promote Cardiovascular Health of Mothers and Young Children
|
N/A | |
Completed |
NCT03356106 -
Screening and Treatment of Obstructive Sleep Apnea in High-risk Pregnancy
|
N/A | |
Recruiting |
NCT05849103 -
Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT03200743 -
Catestatin and Hypertension in Pregnancy
|
N/A | |
Terminated |
NCT04343235 -
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
|
Phase 4 | |
Completed |
NCT01508208 -
Comparison of Urine Protein/Creatinine Ratio With 24-hour Urine Protein Excretion in Woman With Hypertensive Disorders
|
N/A | |
Active, not recruiting |
NCT04580927 -
Breastfeeding and Postpartum Cardiovascular Health
|
N/A | |
Recruiting |
NCT03858595 -
Optimizing Gestational Weight Gain, Birth Weight and Other Perinatal Outcomes Among Pregnant Women at Risk of Hypertension in Pregnancy
|
N/A | |
Recruiting |
NCT05655936 -
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
|
N/A | |
Completed |
NCT02523781 -
Evaluation of an Information Pamphlet for Postpartum Women That Had a Hypertensive Pregnancy
|
N/A | |
Completed |
NCT01736826 -
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
|
||
Completed |
NCT03556761 -
Furosemide for Accelerated Recovery of Blood Pressure Postpartum
|
Phase 2 | |
Completed |
NCT00949260 -
Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-Invasive Bio-Reactance
|
N/A | |
Active, not recruiting |
NCT04012151 -
Arm and Finger Measurement for Blood Pressure Surveillance
|
||
Completed |
NCT04615624 -
Furosemide vs. Placebo for Severe Antepartum Hypertension
|
Phase 3 |